Jen Running Deer & Ayesha Misquith at our research centre in Seattle.

Partnering & innovation

Our approach to partnering

A century of experience turning novel ideas into medicines

Jen Running Deer & Ayesha Misquith at our research centre in Seattle.

Our approach to partnering

We are interested in novel targets, innovative compounds and technologies that address unmet medical needs, and have the potential to be disease modifying, for people living with a serious chronic disease.

Partnerships based on long-term commitment and mutual interest, and open innovation platforms that share knowledge and data, are key to fostering this innovation.

From universities and biotech companies worldwide, to individual scientists and entrepreneurs, our ability to meet our goals depends on working with you.

There are millions of people living with a serious chronic disease relying on us. 

Our approach to partnering

We are proud to have a team of highly skilled scientists and technical experts leading our partnering process. Learn more about our approach to partnering in this short film.

Our partnering approach

Why collaborate with us?

What we offer

  • Industry leading capabilities in developing, manufacturing, and commercialising biological therapies.
  • Sustainable and trust-based relationships, with  bespoke engagement models and deal terms.

What we seek

  • Pipeline partners to develop innovative products that resolve unmet medical needs.
  • Commercial partners to make our products accessible to patients around the world.  

Our current partnership models

Public-private partnerships

We take part in public-private partnerships where they offer an opportunity to help people living with a  serious chronic disease.

One example is out involvement in a new European collaborative research project Hypo-RESOLVE - an international consortium of experts from academia, industry and civil society. The project aims to provide evidence-based insights into all aspects of hypoglycaemia to better understand its impact on people living with diabetes.

Research collaborations

Collaborations with external partners are essential to our R&D efforts. We constantly seek new partnerships with leading individual experts and research teams within biotechnology, academia, as well as with other pharmaceutical companies.

Licensing deals

We are always interested in gaining access to the latest relevant innovation and research, and we regularly license intellectual property rights to new technologies or assets from leading external partners. License agreements can be structured in many ways, but our objective is always to expand our pipeline with new exciting assets and/or to support projects with critical technologies


We will also consider the acquisition of small start-ups or parts of biotech companies in cases where there is a good match in complementary expertise and mutual interest.

Types of partnerships

Novo Nordisk colleagues in the lab

Passionate about proteins…and more

We have nearly a century of expertise working with proteins and peptides. In recent years, we have increased our research technology platforms to include stem cells, RNA interference and genome editing. To realise the full potential of these research technologies, we are pioneering innovation together with our external partners. This included broadening our commitment to a range of new collaborations, both within our current therapy areas, and in new disease areas and technologies.

Open innovation. Novo Nordisk colleagues talking sat down around a table.

The promise of digital solutions

Despite the availability of effective pharmacotherapies, there is a high unmet need and economic burden in ensuring people with diabetes and obesity on pharmacotherapy remain in control of their disease. Multiple factors limit the best possible outcomes. To change this, we are investing in digital and technological innovations to address these real-world inefficiencies and better support patients and healthcare systems in overall disease management

Meet our partnering teams

Our highly skilled scientists and technology experts leading the partnering process are ready to hear from you.